MORGAN STANLEY PLC/PUT/ELI LILLY & CO/650/0.01/20.12.24 | Market Closed - Bid/Ask 10:59:45 02/07/2024 pm IST | After market 01:28:47 am | |||
| 0.078 EUR | +13.04% |
|
0.08 | +2.56% |
| Current month | +2.99% | ||
| 1 month | -50.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 0.078 | +13.04% |
| 01/24/01 | 0.069 | +2.99% |
| 28/24/28 | 0.067 | -2.90% |
| 27/24/27 | 0.069 | -2.82% |
| 26/24/26 | 0.071 | +2.90% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 10:59 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME3E8J |
| ISIN | DE000ME3E8J8 |
| Date issued | 10/11/2023 |
| Strike | 650 $ |
| Maturity | 20/12/2024 (171 Days) |
| Parity | 100 : 1 |
| Emission price | 0.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.01 € |
|---|---|
| Lowest since issue | 0.064 € |
| Spread | 0.008 € |
| Spread % | 9.41% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Warrants
- Warrant
